1. Home
  2. CNM vs IBRX Comparison

CNM vs IBRX Comparison

Compare CNM & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core & Main Inc.

CNM

Core & Main Inc.

SELL

Current Price

$42.66

Market Cap

8.2B

ML Signal

SELL

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$6.26

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNM
IBRX
Founded
1996
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Durable Goods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
8.2B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
CNM
IBRX
Price
$42.66
$6.26
Analyst Decision
Buy
Strong Buy
Analyst Count
15
4
Target Price
★ $54.29
$14.25
AVG Volume (30 Days)
2.0M
★ 12.5M
Earning Date
12-08-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
8.45
★ 38.71
EPS
★ 1.34
N/A
Revenue
★ $7,647,000,000.00
$113,288,000.00
Revenue This Year
$2.51
$99.98
Revenue Next Year
$4.23
$108.29
P/E Ratio
$32.76
★ N/A
Revenue Growth
2.77
★ 668.31
52 Week Low
$39.42
$1.95
52 Week High
$59.66
$12.43

Technical Indicators

Market Signals
Indicator
CNM
IBRX
Relative Strength Index (RSI) 44.29 35.32
Support Level $40.85 N/A
Resistance Level $43.51 $8.62
Average True Range (ATR) 1.76 0.55
MACD -0.32 -0.23
Stochastic Oscillator 6.20 14.11

Price Performance

Historical Comparison
CNM
IBRX

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: